熊去氧胆酸治疗原发性胆汁性胆管炎患者疗效及对血清Nrf2和HO-1水平的影响

doi:10.3969/j.issn.1672-5069.2022.02.015

摘要/Abstract

摘要： 目的探讨熊去氧胆酸(UDCA)治疗原发性胆汁性胆管炎和肝硬化(PBC)患者疗效及对血清核因子相关因子2(Nrf2)和血红素加氧酶-1(HO-1)水平的影响。方法 2017年1月～2020年1月我院诊治的原发性胆汁性胆管炎患者31例和原发性胆汁性肝硬化患者34例(Child A 级 15 例,Child B 级 12 例,Child C级 7例),给予所有患者UDCA治疗。另选43例健康人作为对照。;采用硫代巴比妥酸化学比色法检测血清丙二醛(MDA),采用黄嘌呤氧化酶法测定血清超氧化物歧化酶(SOD),采用ELISA法检测血清Nrf2和HO-1水平。结果治疗前,肝硬化患者血清GGT和ALP水平分别为(389.4±29.7)U/L和(457.9±73.8)U/L,显著高于胆管炎组[分别为(173.5±16.4)U/L和(298.3±52.1)U/L,P<0.05];在治疗观察12个月末,血清GGT和ALP水平分别为(174.1±10.4)U/L和(144.6±24.5)U/L,仍显著高于胆管炎组[分别为(72.6±7.1)U/L和(95.7±11.6)U/L,P<0.05];健康人血清Nrf2、HO-1、MDA和SOD水平分别为(182.3±30.6)U/L、(12.2±2.1)U/L、(4.1±0.7)mol/L和(102.3±17.8)U/mL;治疗后,肝硬化组血清Nrf2、HO-1和MDA水平分别为(712.6±100.1)U/L、(25.1±4.3)U/L和(7.6±1.3)mol/L,显著高于胆管炎组[分别为(665.3±90.5)U/L、(21.3±3.8)U/L和(6.5±1.1)mol/L,P<0.05],而血清SOD水平为(80.6±14.5)U/mL,显著低于胆管炎组[(90.8±15.6)U/mL,P<0.05];治疗后,不同Child分级的肝硬化患者血清Nrf2、HO-1、MDA和SOD水平比较,差异均无统计学意义(P＞0.05)。结论应用UDCA治疗原发性胆汁性胆管炎和肝硬化患者可改善胆汁淤积,促进肝功能恢复,可能与其抑制了氧化应激反应,提升血清Nrf2和HO-1水平有关。

关键词: 原发性胆汁性胆管炎, 肝硬化, 熊去氧胆酸, 核因子相关因子2, 血红素加氧酶-1, 治疗

Abstract: Objective The aim of this study was to summarize the efficacy of ursodeoxycholic acid (UDCA) in the treatment of patients with primary biliary cholangitis (PBC) and cirrhosis and its effect on serum nuclear factor-related factor 2 (Nrf2) and hemeoxygenase-1 (HO-1) levels. Methods 31 patients with PBC and 34 patients with primary biliary cirrhosis (Child A in 15, Child B in 12 and Child C in 7 cases) were recruited in our hospital between January 2017 and January 2020, and 43 healthy persons were selected as control group. The patients with cholangitis and cirrhosis were all treated with UDCA for 12 months. Serum malondialdehyde (MDA), superoxide dismutase (SOD), Nrf2 and HO-1 levels were detected. Results At presentation, serum GGT and ALP levels in patients with primary biliary cirrhosis were (389.4±29.7)U/L and (457.9±73.8)U/L, both significantly higher than [(173.5±16.4)U/L and (298.3±52.1)U/L, respectively, P<0.05] in patients with primary biliary cholangitis; at the end of 12 month treatment, serum GGT and ALP levels in patients with primary biliary cirrhosis were(174.1±10.4)U/L and (144.6±24.5)U/L, still significantly higher than [(72.6±7.1)U/L and (95.7±11.6)U/L, respectively, P<0.05] in patients with primary biliary cholangitis; serum Nrf2, HO-1, MDA and SOD levels in healthy individuals were (182.3±30.6)U/L, (12.2±2.1)U/L, (4.1±0.7)mol/L and (102.3±17.8)U/mL; at 12 month observation, serum Nrf2, HO-1 and MDA levels in patients with primary biliary cirrhosis were (712.6±100.1)U/L, (25.1±4.3)U/L and (7.6±1.3)mol/L, all significantly higher than [(665.3±90.5)U/L, (21.3±3.8)U/L and (6.5±1.1)mol/L, respectively, P<0.05], while serum SOD level was (80.6±14.5)U/mL, significantly lower than [(90.8±15.6)U/mL, P<0.05] in patients with primary biliary cholangitis; there were no significant differences as respect to serum Nrf2, HO-1, MDA and SOD levels in cirrhotics with Child class A, B and C(P＞0.05). Conclusion The continuous administration of UDCA could improve the liver function test normalization in patients with PCB and cirrhosis, which might be related to the amelioration of cholestasis, inhibition of oxidative stress, and increase serum Nrf2 and HO-1 levels.

Key words: Primary biliary cholangitis, Liver cirrhosis, Ursodeoxycholic acid, Nuclear factor related factor 2, Heme oxygenase-1, Therapy

曾议, 李国, 李红翠, 彭雅松, 田峰, 王小军. 熊去氧胆酸治疗原发性胆汁性胆管炎患者疗效及对血清Nrf2和HO-1水平的影响[J]. 实用肝脏病杂志, 2022, 25(2): 211-214.

Zeng Yi, Li Guo, Li Hongcui, et al. Efficacy of ursodeoxycholic acid in the treatment of patients with primary biliary cholangitis and cirrhosis and its effect on serum Nrf2 and HO-1 levels[J]. Journal of Practical Hepatology, 2022, 25(2): 211-214.

参考文献

[1] Tanaka A, Leung PS, Gershwin ME. Environmental basis of primary biliary cholangitis. Exp Biol Med, 2018, 243(2):184-189.
[2] Danford CJ, Trivedi HD, Papamichael K, et al. Osteoporosis in primary biliary cholangitis. World J Gastroenterol, 2018, 24(31):3513-3520.
[3] Tanaka A, Leung PSC, Gershwin ME. Pathogen infections and primary biliary cholangitis. Clin Exp Immunol, 2019, 195(1):25-34.
[4] Chapman RW. Cost effectiveness of using ursodeoxycholic acid to treat primary biliary cholangitis. Br J Hosp Med, 2018, 79(8):460-464.
[5] Pares A, Albillos A, Andrade RJ, et al. Primary biliary cholangitis in Spain results of aDelphi study of epidemiology, diagnosis, follow-up and treatment. Rev Esp Enferm Dig, 2018, 110(10):641-649.
[6] Chapman RW. Cost effectiveness of using ursodeoxycholic acid to treat primary biliary cholangitis. Br J Hosp Med, 2018, 79(8):460-464.
[7] 黄丽华, 杨正兵, 谭礼让. 熊去氧胆酸联合非诺贝特治疗PBC患者血清TGF-β,IFN-γ和IL-10水平变化. 实用肝脏病杂志, 2020, 23(4):520-523.
[8] Kitamura H, Motohashi H. NRF2 addiction in cancer cells. Cancer Sci, 2018, 109(4):900-911.
[9] 鲁稳梁, 李剑峰, 巩红岩, 等. Nrf2信号通路在小鼠内毒素性急性肺损伤时内质网应激反应中的作用. 中华麻醉学杂志, 2019, 39(4):494-497.
[10] 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015). 中华传染病杂志, 2016, 34(7):385-394.
[11] 中华医学会肝病学分会、消化病学分会、感染病学分会.胆汁淤积性肝病诊断和治疗共识(2015).实用肝脏病杂志,2016,19(6):Ⅰ-ⅩⅠ.
[12] Drazilova S , Babinska I , Gazda J , et al. Epidemiology and clinical course of primary biliary cholangitis in Eastern Slovakia. Int J Public Health, 2020, 65(5):683-691.
[13] Galoosian A, Hanlon C, Zhang J,et al. Clinical updates in primary biliary cholangitis: Trends, epidemiology, diagnostics, and new therapeutic approaches. J Clin Transl Hepatol, 2020, 8(1):49-60.
[14] Cauldwell M, Mackie FL, Steer PJ, et al. Pregnancy outcomes in women with primary biliary cholangitis and primary sclerosing cholangitis: a retrospective cohort study. BJOG, 2020, 127(7):876-884.
[15] Hayashi M , Abe K , Fujita M , et al. Serum Gas6 and Axl as non‐invasive biomarkers of advanced histological stage in primary biliary cholangitis. Hepatol Res, 2020, 50(12):1337-1346.
[16] 齐敬聪, 邢文静, 杜洋, 等. 熊去氧胆酸联合微生态制剂治疗原发性胆汁性胆管炎患者对肠道菌群的影响. 实用肝脏病杂志, 2020, 23(4):524-527.
[17] 李琪, 曾阿娟, 孟雯, 等. 原发性胆汁性胆管炎患者胆囊病变临床分析. 实用肝脏病杂志, 2019, 22(6):924-927.
[18] Chiang JYL, Ferrell JM. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. Am J Physiol Gastrointest Liver Physiol, 2020, 318(3):554-573.
[19] Bereczki D Jr, Balla J, Bereczki D. Heme oxygenase-1: Clinical relevance in ischemic stroke. Curr Pharm Des, 2018, 24(20):2229-2235.
[20] Gu M , Jin J , Ren C , et al. Akebia saponin D suppresses inflammation in chondrocytes via the NRF2/HO-1/NF-κB axis and ameliorates osteoarthritis in mice. Food Funct, 2020, 11(12):10852-10863.
[21] Huang X, Fei GQ, Liu WJ, et al. Adipose-derived mesenchymal stem cells protect against CMS-induced depression-like behaviors in mice via regulating the Nrf2/HO-1 and TLR4/NF-κB signaling pathways. Acta Pharmacol Sin, 2020, 41(5):612-619.
[22] Kouroumalis E, Samonakis D, Voumvouraki A. Biomarkers for primary biliary cholangitis: current perspectives. Hepat Med, 2018, 18(10):43-53.
[23] Suraweera D, Fanous C, Jimenez M, et al. Risk of cardiovascular events in patients with primary biliary cholangitis - systematic review. J Clin Transl Hepatol, 2018, 6(2):119-126.
[24] Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases. Hepatology, 2019, 69(1):394-419.
[25] Nguyen T V , Piao C H , Fan Y J , et al. Anti-allergic rhinitis activity of α-lipoic acid via balancing Th17/Treg expression and enhancing Nrf2/HO-1 pathway signaling. Sci Rep, 2020, 10(1):12528-12531.
[26] Hada Y, Uchida HA, Otaka N, et al. The protective effect of chlorogenic acid on vascular senescence via the Nrf2/HO-1 pathway. Int J Mol Sci, 2020, 21(12):4527-4530.
[27] Yuan B, Huang H, Qu S, et al. Gastrodin pretreatment protects liver against ischemia-reperfusion injury via activation of the Nrf2/HO-1 pathway. Am J Chin Med, 2020,48(5):1159-1178.
[28] Choi YH. Activation of the Nrf2/HO-1 signaling pathway contributes to the protective effects of coptisine against oxidative stress-induced DNA damage and apoptosis in HaCaT keratinocytes. Gen Physiol Biophys, 2019, 38(4):281-294.